1. Inhibitory killer cell immunoglobulin-like receptor ( iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation.
- Author
-
Bastos‐Oreiro, Mariana, Anguita, Javier, Martínez‐Laperche, Carolina, Fernández, Lucía, Buces, Elena, Navarro, Almudena, Pascual, Cristina, Pérez‐Corral, Ana, Balsalobre, Pascual, Muñoz, Cristina, Kwon, Mi, Serrano, David, Perez‐Martinez, Antonio, Buño, Ismael, Gayoso, Jorge, and Díez‐Martín, José Luís
- Subjects
- *
KILLER cells , *IMMUNOGLOBULIN receptors , *STEM cell transplantation , *CYCLOPHOSPHAMIDE , *T cells - Abstract
Alloreactivity triggered by interaction between killer cell immunoglobulin-like receptors ( KIRs) and natural killer ( NK) cells plays a role in the graft-versus-tumor effect after hematopoietic stem cell transplantation ( SCT). Our aim in this study was to evaluate this role in the setting of T-cell-repleted haploidentical SCT with postinfusion high-dose cyclophosphamide ( PT-Cy). We included 33 patients. Among patient-donor pairs with at least 1 inhibitory KIR ( iKIR) gene mismatch, event-free survival ( EFS) and cumulative incidence of relapse 1 year after transplant were significantly better (85% vs. 37% [ P = 0.008] and 18% vs. 46% [ P = 0.041], respectively). A subanalysis in 12 patients with Hodgkin's lymphoma ( HL) showed an improvement in EFS 1 year after transplant in those patients with KIR ligand mismatch (100% vs. 25%, P = 0.012), although overall survival ( OS) was not affected (85% vs. 80%, P = 0.2). Eight of 12 patient-donors pairs presented iKIR mismatches. Of note, this outcome was better in the small subgroup, both for EFS (100% vs. 25%, P = 0.012) and for OS (100% vs. 37%, P = 0.004). Our data suggest that in the setting of T-cell-repleted haploidentical SCT with PT-Cy, iKIR mismatch is associated with improved survival, with particularly good results for both iKIR and KIR ligand mismatches in patients with HL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF